ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2009

SAN DIEGO—(BUSINESS WIRE)—Oct. 6, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will present at the JMP Securities HealthcareFocus Conference on Tuesday, October 6, 2009 at 3:00 p.m. Eastern Timeat The New York Palace Hotel in New York City.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through October 20, 2009.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA’s product candidates includepimavanserin in Phase III for Parkinson’s disease psychosis incollaboration with Biovail, a product candidate in Phase II for chronicpain and a product candidate in Phase I for glaucoma, both incollaboration with Allergan, as well as additional compounds inIND-track development. All of the product candidates in ACADIA’spipeline emanate from discoveries made using its proprietary drugdiscovery platform. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director,Investor Relations
Thomas H. Aasen, Vice President and ChiefFinancial Officer
858-558-2871